Prognostic impact of neutrophil-to-lymphocyte ratio (NLR) in patients with unresectable biliary tract cancer treated with gemcitabine, cisplatin, and durvalumab
Abstract Background Biliary tract cancer (BTC) is a type of malignancy that is challenging to manage. Further, advanced-stage BTC has poor prognosis. Based on the recent TOPAZ-1 trial, adding durvalumab to gemcitabine and cisplatin significantly improves survival in unresectable BTC, thereby making...
Guardat en:
| Autors principals: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2025-07-01
|
| Col·lecció: | World Journal of Surgical Oncology |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s12957-025-03834-x |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|